# A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

> **NCT01372163** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 35 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** PF-05190457 or Placebo
- **DRUG:** PF-05190457 or Placebo
- **DRUG:** PF-05190457 or Placebo
- **DRUG:** PF-05190457 or Placebo
- **DRUG:** PF-05190457 or Placebo
- **DRUG:** PF-05190457 or Placebo
- **DRUG:** PF-05190457 or Placebo

## Key facts

- **NCT ID:** NCT01372163
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** B3301002 was discontinued on 18 April 2012 for strategic reasons.There were no safety concerns leading to discontinuation of this study.
- **Last updated:** 2012-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01372163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01372163, "A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01372163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*